Vol 15, No 2 (2019)
Case report
Published online: 2019-05-17
Nivolumab in the treatment of advanced renal cell carcinoma
Oncol Clin Pract 2019;15(2):124-126.
Abstract
Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody approved for the treatment of advanced and metastatic renal cell carcinoma. Treatment with nivolumab is characterised by favourable toxicity profile. The occurrence of grade 3 and 4 toxicity during the therapy is low. This article describes a medical history of a patient with metastatic renal cell carcinoma treated with nivolumab.
Keywords: renal cell carcinomaimmunotherapynivolumab
References
- Wysocki P, Borkowski T. Nowotwory układu moczowo-płciowego. In: Krzakowski M. ed. Onkologia kliniczna, t. 2. Via Medica , Gdańsk 2015: 751–760.
- Escudier B, Porta C, Schmidinger M, et al. ESMO Guidelines Committee. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(Suppl 5): 58–68.
- Krawczyk P, Wojas-Krawczyk K. Immunoterapia ukierunkowana na immunologiczne punkty kontroli. In: Wysocki P. ed. Immunoonkologia. ViaMedica , Gdańsk 2016: 47–57.
- Motzer R, Escudier B, McDermott D, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015; 373(19): 1803–1813.
- Xu JX, Maher VE, Zhang L, et al. FDA approval summary: nivolumab in advanced renal cell carcinoma after anti-angiogenic therapy and exploratory predictive biomarker analysis. Oncologist. 2017; 22(3): 311–317.
- Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17(8): 2530–2540.
- Zhao X, Suryawanshi S, Hruska M, et al. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Ann Oncol. 2017; 28(8): 2002–2008.
- Brahmer J, Lacchetti C, Schneider B, et al. American Society of Clinical Oncology. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018; 36(17): 1714–1768.
- Eisen T, Sternberg CN, Robert C, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst. 2012; 104(2): 93–113.
- Escudier B, Sharma P, McDermott D, et al. CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol. 2017; 72(6): 962–971.